Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neurizon Raises A$4.3 Million, Targets Further A$2 Million as It Clears Convertible Notes

NUZ: $0.065 -24.42% · MC: $48M

Neurizon Therapeutics has secured firm commitments for a A$4.3 million share placement and is targeting a further A$2 million through a shareholder plan, replacing a potential drawdown under its convertible-note facility. It has redeemed all remaining notes, leaving none on issue and removing potential conversion dilution; the company says it remains funded through the HEALEY trial’s expected topline readout. The new funding follows its October quarterly update, which reported A$11 million in cash and said it was fully funded through the readout.

Source announcements: 2026-11-02 09:32 to 2026-11-02 09:55 Sydney time
Story updated 2026-11-02 10:01 Sydney time
SourcesProposed issue of securities - NUZFirm commitments to raise A$4.3m and announcement of SPPProposed issue of securities - NUZRedemption of all remaining Obsidian convertible notesNotification of cessation of securities - NUZWithdrawal of Resolution 4 from Notice of AGM
Comments